Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.11.031
Abstract: BACKGROUND Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for naïve patients with intermediate or poor risk prognosis (International… read more here.
Keywords: renal cell; line; ipilimumab failure; metastatic renal ... See more keywords